SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (5005)8/13/2001 5:27:41 PM
From: Biomaven  Read Replies (1) of 10280
 
IJ,

Xopenex predictions:

Looking back at last year, Xopenex sales were as follows ($millions):

Q1: 13.9
Q2: 9.6
Q3: 10.2
Q4: 23.5

and this year:

Q1: 28.5
Q2: 33.0

So Q3 did marginally beat Q2 last year, but on a much lower base and in the context of a rapidly improving market share. It's hard to disentangle the seasonality from the market share gain, particularly as SEPR's seasonality seems to be more pronounced than the overall market and may even be greater than last year. So I'm being conservative and figuring they'll drop some in Q3, perhaps even when compared with Q1. However Q4 should be a record - maybe they'll even hit $50m for Q4.

So I agree that $120m is easily doable this year, with a shot at $130m or better.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News